# ERJ Podcast January 2026: Cannabis and the Lung | European Respiratory Society > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-pulmonary-health-erj-podcast-2026/ > **Published:** 2026-04-24T12:10:27-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:03:29-04:00 > **Clinical Summary:** Explore cannabis pulmonary health insights from the ERJ Podcast January 2026, focusing on respiratory effects and clinical counseling for patients. --- โœฆ New CED Clinical Relevance #50 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. ResearchSafetyPolicy Clinical Summary The European Respiratory Societyโ€™s January 2026 podcast addresses the impact of cannabis use on pulmonary health, a topic of growing clinical relevance as [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) expands access and patient use increases. The discussion likely covers respiratory effects of different consumption methods, including smoking, vaping, and edibles, along with mechanisms of potential lung injury and inflammation. For clinicians, understanding cannabis-related respiratory risks is essential to providing comprehensive counseling to patients, particularly those with underlying lung disease, asthma, or COPD who may be considering cannabis for symptom management. The podcast content serves to integrate evidence-based respiratory medicine perspectives into clinical conversations about cannabis use, which many patients may not spontaneously disclose without direct inquiry. Clinicians should be prepared to discuss both the potential therapeutic applications of cannabis and its demonstrated pulmonary harms when taking patient histories and counseling on substance use. Healthcare providers should routinely ask about [cannabis consumption methods](https://cedclinic.com/cannabis-anxiety-relief-tips/) and frequency to identify patients at risk for cannabis-related respiratory complications and provide appropriate prevention or cessation counseling. Clinical Perspective As cannabis use becomes increasingly normalized and legalized across multiple jurisdictions, respiratory clinicians should be prepared to discuss pulmonary risks with patients, though the evidence base remains incomplete due to decades of prohibition limiting rigorous research. While combusted cannabis clearly irritates airways and may contribute to chronic bronchitis and airway obstruction similar to tobacco, the specific dose-response relationships, long-term cancer risk, and relative safety of different consumption methods (smoking, vaping, edibles) are not yet established with the same certainty as for cigarettes. Healthcare providers should recognize that many patients perceive cannabis as safer than tobacco and may underestimate respiratory hazards, particularly given the overlap between cannabis and tobacco use in some populations and the confounding variable of concurrent smoking exposure. In clinical practice, a straightforward approach includes asking about cannabis use frequency and method during respiratory assessments, counseling patients about the known risks of smoking and the theoretical advantages of non-combust ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan โ†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion โ†’](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [๐• Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+ERJ+Podcast+January+2026%3A+%3Cb%3ECannabis%3C%2Fb%3E+and+the+lung+%7C+European+Respiratory+Society+%40drcaplan&url=https%3A%2F%2Fpublications.ersnet.org%2Fcontent%2Ferj%2F67%2F1%2F26e6701)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fpublications.ersnet.org%2Fcontent%2Ferj%2F67%2F1%2F26e6701)[๐Ÿฆ… Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+ERJ+Podcast+January+2026%3A+%3Cb%3ECannabis%3C%2Fb%3E+and+the+lung+%7C+European+Respiratory+Society+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fpublications.ersnet.org%2Fcontent%2Ferj%2F67%2F1%2F26e6701)[๐Ÿ“ท Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[๐Ÿ“ Read more on Substack](https://substack.com/@doctorapproved)[๐Ÿ”” Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 436 Items โ€” March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items โ€” March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) - [CED Digest: 392 Items โ€” March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) ๐Ÿ“ฐ Source: [https://publications.ersnet.org/content/erj/67/1/26e6701](https://publications.ersnet.org/content/erj/67/1/26e6701) Further Reading Cannabis Policy WireCED Regulatory Digest, Since Last Digest, 1 items Evidence Watch[Neuropathic Pain Severity Is Associated With Opioid Use in Adults With Traumatic Spinal Cord Injury: A Spinal Cord Injury Model System Study.](https://cedclinic.com/opioid-use-neuropathic-pain-spinal-cord-injury/) Research Digest[Research Digest: 10 Recent Studies โ€“ April 22, 2026](https://cedclinic.com/recent-cannabinoid-clinical-research-april-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Approaching Conversations About Cannabis Use with Patients & Caregivers โ€“ Oncology Times Learn strategies for discussing cannabis use with patients and caregivers to improve clinical communication and care. Read More [DC Mayor Proposes To Let Medical Marijuana And Alcohol Companies Partner On THC Drinks](https://cedclinic.com/dc-cannabis-beverage-regulation-medical-marijuana-thc-drinks/) Explore emerging cannabis policy developments impacting medical marijuana and alcohol partnerships in DC. [Explore Policy](https://cedclinic.com/dc-cannabis-beverage-regulation-medical-marijuana-thc-drinks/) [The Best CBD for Immune Support and Daily Resilience in 2026 | stupidDOPE | Est. 2008](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) Discover top CBD products supporting immune health and resilience in 2026 with expert insights. [Discover CBD](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR ยง 164.514(b)) and criteria for secondary research exemption under 45 CFR ยง 46.104(d)(4).